Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
Location: United States, Massachusetts, Lexington
Employees: 51-200
Total raised: $127M
Founded date: 2006
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.11.2021 | - | $65M | - |
| 17.05.2021 | - | $32M | - |
| 12.06.2017 | - | $30M | Hercules C... |
Mentions in press and media 16
| Date | Title | Description | Source |
| 19.01.2023 | Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the... | Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Area... | en.prnasia... |
| 08.11.2021 | Concert Pharmaceuticals Announces $65 Million Financing Fina... | Concert Pharmaceuticals Announces $65 Million Financing Financing Provided by Leading Healthcare Fu... | marketscre... |
| 04.11.2021 | Concert Pharmaceuticals Announces $65 Million Financing | Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into an agreement w... | marketscre... |
| 17.05.2021 | CONCERT PHARMACEUTICALS, INC. Concert Pharmaceuticals : Ann... | Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that Vertex Pharmaceuticals Incorporate... | marketscre... |
| 13.11.2018 | Concert’s initial alopecia data fall short against Pfiz... | An interim analysis of mid-stage data on Concert Pharmaceuticals’ $CNCE JAK inhibitor for ... | endpts.com... |
| 27.04.2018 | Vertex's rapid-fire PhIII program hits a roadblock at th... | Vertex’s R&D team doesn’t make many mistakes. So during yesterday’s Q1 call, a group of an... | endpts.com... |
| 22.12.2017 | Synergy CEO passes torch to CCO Troy Hamilton; Preside... | Troy Hamilton → Marking a new phase for the biotech, Synergy Pharmaceuticals $SYGP announc... | endpts.com... |
| 12.06.2017 | Concert Pharmaceuticals Announces $30 Million Venture Debt F... | LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that... | citybizlis... |
| 12.06.2017 | Concert Pharmaceuticals Announces $30 Million Venture Debt F... | LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that... | archive.ci... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
Show more